Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD).
“Satralizumab is a recycling antibody created utilizing Chugai’s proprietary antibody engineering technologies. We are delighted by the FDA’s designation for this innovative antibody based on the results of a Chugai-initiated global Phase III study” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “Satralizumab is designed to inhibit signaling of the inflammatory cytokine IL-6, which is known to play a role in the pathogenesis of NMO/NMOSD. We continue our efforts to hopefully bring satralizumab as a new treatment option as soon as possible to people living with this devastating disease with no approved drugs.”
The designation for satralizumab is based on data from the Phase III study (SAkuraSky study, NCT02028884) evaluating satralizumab added to baseline therapy. This is the seventh Breakthrough Therapy Designation received for four drugs created by Chugai.
Press release issued on October 15, 2018
Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018
About Breakthrough Therapy
Breakthrough Therapy Designation was adopted as part of the FDA Safety and Innovation Act (FDASIA) enacted in July 2012 aiming at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms. In order to grant Breakthrough Therapy Designation, preliminary clinical evidence is required demonstrating that the drug may have substantial improvement on at least one clinically significant endpoint over existing therapies. Breakthrough Therapy Designation includes the features of a Fast Track designation, with the addition of intensive guidance on efficient drug development as well as organizational commitment from FDA.
About Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, lifelong, and debilitating autoimmune disease of the central nervous system (CNS) characterized by inflammatory lesions in the optic nerves and spinal cord. Patients with NMOSD frequently experience a relapsing disease course with repeated attacks leading to accumulating neurological damage and disability. Symptoms may include visual impairment, motor disability, and loss of quality of life. In some cases, attacks of NMOSD result in death.
NMOSD pathogenesis is thought to involve AQP4-IgG autoantibody entry into the CNS, however approximately one-third of patients with NMOSD are AQP4-IgG seronegative1)-4). The inflammatory cytokine IL-6 is now emerging as an important factor in NMOSD pathogenesis.
Diagnostic criteria introduced in 2006 for neuromyelitis optica were characterized by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). These were revised in 2007 with the definition of NMOSD, proposed for diseases with either optic neuritis or myelitis. In 2015, the definition of NMOSD was further revised to include a broader spectrum of disease. The diagnostic term NMOSD is now widely used5).
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totalled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.
|1.||Jarius S, Ruprecht K, Wildemann B et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012;9:14.|
|2.||Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.|
|3.||Marignier R, Bernard-Valnet R, Giraudon P et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013;80:2194-200.|
|4.||Takahashi T, Fujihara K, Nakashima I et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-43.|
|5.||Wingerchuk DM, Banwell B, Bennett JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.|
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
IHS Markit to Integrate Cappitech Technology In SFTR Reporting Solution25.6.2019 19:23:00 EEST | Tiedote
Cappitech, a leading provider of regulatory reporting and intelligence solutions for the financial services industry and IHS Markit, a world leader in critical information, analytics and solutions, today announced an alliance to deliver the IHS Markit Securities Financing Transactions Regulation (SFTR) solution. The IHS Markit SFTR solution will integrate Cappitech’s award-winning platform CapptivateTM to offer a best-of-breed solution that will meet the industry’s SFTR trade reporting needs by automating and streamlining transaction reporting to trade repositories for all securities finance instruments. It will also support out-of-the-box MiFID II reporting for additional instruments that will be in scope when SFTR goes live. Pierre Khemdoudi, Managing Director & Global Co-Head of Equities, Data and Analytics at IHS Markit, said: “We look forward to leveraging Cappitech’s technology to deliver a regulatory reporting solution that can help manage the comprehensive requirements of SFTR.
Moody’s Analytics CreditLens™ Solution Adopted by Over 100 Firms25.6.2019 16:00:00 EEST | Tiedote
Moody’s Analytics, a leading provider of financial intelligence, announced today that the CreditLens credit-lifecycle-management solution has been adopted by over 100 firms since its launch. Built on the latest cloud-based technology, the CreditLens platform helps businesses digitally transform their commercial credit processes to make faster and better-informed decisions. The platform uses the latest AI and machine learning technology to facilitate process automation, and help clients improve efficiency, reduce errors, and streamline workflows. "We are honored that our clients have embraced the CreditLens solution and enabled us to reach this milestone,” said Annie Choi, Senior Director at Moody’s Analytics. “Our goal is to provide the best credit lifecycle management solution in the market, informed by our award-winning proprietary data, and enabled by the modern technologies our clients want to use.” “Technological innovation is accelerating at a rapid pace, creating opportunities f
Modern Governance 3.0: Modern Governance Extends Beyond the Boardroom to Allow Secure Sharing of Files and Collaboration with Auditors, Regulators and Other Third Parties25.6.2019 16:00:00 EEST | Tiedote
In its next major extension to support modern governance, Diligent announced today the launch of Secure File Sharing and Secure Meeting Workflow applications, as part of the Diligent Governance Cloud. These groundbreaking applications enable completely secure collaboration not only between board members and executives, but also reaching beyond the boardroom including auditors, regulators and other key third party stakeholders. This significantly raises the bar on security and information governance for organizations operating in this digital, mobile and social era. In today’s fast-paced world, threats come at light speed – from every angle. Leading organizations must set increasingly higher standards to protect against cyber attacks and leaks, while at the same time work collaboratively with more outside parties. Even competent leaders can have blind spots when it comes to the handling of highly sensitive files, specifically in preparation for a board meeting, sharing documents haphaza
Transphorm Strengthens 900 V GaN Portfolio with Second FET25.6.2019 16:00:00 EEST | Tiedote
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability high-voltage (HV) Gallium Nitride (GaN) semiconductors—today introduced its second 900 V FET, the Gen III TP90H050WS, enhancing the industry’s only 900 V GaN product line. These devices now enable three-phase industrial systems and higher voltage automotive electronics to leverage GaN’s speed, efficiency and power density. Further, the new FET’s platform is based on Transphorm’s 650 V predecessor, the only JEDEC- and AEC-Q101-qualified HV GaN technology. As such, system developers can design with confidence in its quality and reliability. The TP90H050WS has a typical on-resistance of 50 mOhm with a 1000 V transient rating, offered in a standard TO-247 package. The TP90H050WS can reach power levels of 8 kW in a typical half bridge while maintaining greater than 99 percent efficiencies. Its figures of merit for Ron*Qoss (resonant switching topologies) and Ron*Qrr (hard switching bridge topologies) are t
BOC Group Announces the Release of ADONIS NP 7.1 – Igniting A New Era of User Inclusion, Insights & BPM Experience25.6.2019 15:26:00 EEST | Tiedote
Today, BOC Group released the latest version of its revolutionary BPM suite, ADONIS NP 7.1. Focusing specially on enriching the ADONIS NP experience for every user, transparency, simplicity and openness were kept at the core of this version’s design. And this release’s flagship feature, the Process Insights Dashboard, is a direct embodiment of that, with its powerful visualization and representation of all key process management information. Tobias Rausch, ADONIS NP product manager, elaborates: “We carefully designed the Insights Dashboard in a way that provides that one-click-access to everything you would need to know about your processes – from process hierarchy, responsible roles, inputs, outputs, to IT, risks, KPIs, as well as quick-links to analyses and reports”. “Essentially, the Insights Dashboard brings an entirely new and simplified way of interacting with the process content, ultimately making ADONIS NP even more user-friendly and intuitive than befo re!" What’s more, the la
MATRIXX Software Joins Linux Foundation Networking to Advance Next Generation of Telco Services25.6.2019 15:05:00 EEST | Tiedote
MATRIXX Software , an innovation powerhouse committed to transforming global commerce, today announced it has joined Linux Foundation Networking (LFN) as a silver member. MATRIXX is participating in the foundation’s programs to provide guidance related to advancing a new generation of services inspired by web-scale best practices. With over 100 members, LFN continues its global drumbeat of ecosystem growth for accelerated development and adoption of open source and open standards-based networking technologies. The Linux Foundation supports the creation of sustainable open source ecosystems by providing financial and intellectual resources, infrastructure, services, events and training. “The LF Networking community is working together to foster industry collaboration and innovation across the entire open networking stack, and increase harmonization across platforms, ecosystems and communities,” said Arpit Joshipura, general manager, Networking, Automation, Edge & IOT, the Linux Foundati
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme